In Vivo CAR Therapies Review Summary
Over the last few years In Vivo CAR Therapies have been increasing in popularity as a potential treatment for various cancer indications and auto-immune diseases.
The lower manufacturing costs of this exciting new modality, in comparison to ex vivo CAR T-cell therapies, make in vivo CAR therapies an attractive prospect for drug developers.
With exclusive data from Beacon, this review contains:
- An overview of the in vivo CAR Therapy landscape and the therapies currently clinically active
- A look at the potential delivery systems and disease indications for in vivo CAR therapies
- An outline of the collaborations and financial deals in the in vivo CAR therapy space
Find out more
Beacon is the essential decision-support tool for developers of complex therapeutics. Our market-defining, proprietary ontologies, combined with the most accurate and comprehensive life sciences data, provide our customers with unparalleled visibility of the drug and trial landscape.
With Beacon, you can make drug development decisions with confidence. This is why 23 of the world’s top 25 drug developers trust us.
